Item 9 Labs (Item 9 Labs) ROCE % : -19.73% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Item 9 Labs's annualized ROCE % for the quarter that ended in Jun. 2023 was -19.73%.

Item 9 Labs ROCE % Historical Data

The historical data trend for Item 9 Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs ROCE % Chart

Item 9 Labs Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

ROCE %

Get a 7-Day Free Trial

-36.91

-193.01

-61.27

-10.00

-28.78

Item 9 Labs Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															-18.51	-84.62	-8.11	-7.68	-19.73

Item 9 Labs ROCE % Calculation

Item 9 Labs's annualized ROCE % for the fiscal year that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2022 )		(A: Sep. 2021 )		(A: Sep. 2022 )
	=	-24.751	/	( ( (116.809 - 14.99)	+	(110.762 - 40.586) )	/ 2 )
	=	-24.751	/	( (101.819	+	70.176)	/ 2 )
	=	-24.751	/	85.9975
	=	-28.78 %

Item 9 Labs's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	-11.856	/	( ( (114.127 - 47.136)	+	(112.015 - 58.813) )	/ 2 )
	=	-11.856	/	( ( 66.991	+	53.202 )	/ 2 )
	=	-11.856	/	60.0965
	=	-19.73 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Item 9 Labs (OTCPK:INLB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Item 9 Labs ROCE % Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Item 9 Labs (Item 9 Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016

Website

https://www.item9labscorp.com

Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.

Executives

Taylor Lawrence X. Iii	director	2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher	director	2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey	director	C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden	director	C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven	officer: Chief Operating Officer	5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson	director, officer: Chief Executive Officer	1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden	director	3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen	officer: CFO, Secretary, Treasurer	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan	10 percent owner	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier	10 percent owner	1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla	director, officer: President	2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md	director, officer: President	10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership	director, officer: President & CEO	10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith	officer: CFO, Secretary, Treasurer	8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson	officer: Chief Operating Officer	8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251